On the 26th of January, the Republic Day, India would launch its first made in India Intranasal vaccine for the Wuhan Virus, also known as the Novel Coronavirus (COVID-19.)
According to sources, the Intranasal vaccine was manufactured by Hyderabad’s Bharat Biotech International Private Limited. On the 6th of September 2022, the Drugs Controller General of India (DCGI) V.G. Somani approved restricted emergency use of the vaccine iNCOVACC (BBV154) for primary two dose schedule, for people above 18 years of age. The intranasal vaccine was jointly developed by the Covaxin maker Bharat Biotech and Washington University, St. Louis. It also became India’s first intranasal vaccine against the Wuhan Virus. Notably, the approval of the intranasal vaccine, iNCOVACC, came after its successful phase I, II and III clinical trials, and would boost India’s COVID-19 vaccination drive. After emergency use approval, earlier this month the vaccine iNCOVACC received approval for adults.
Now, after the approval earlier, the pharma company would officially launch the vaccine for the public. Dr. Krishna Ella, the Chairman of Bharat Biotech made an official announcement in this regard and said, “Our nasal vaccine will be officially launched on Republic Day on January 26,” said Ella while participating in a session during the 8th edition of the India International Science Festival (IISF) that began at the Maulana Azad National Institute of Technology (MANIT.)
Furthermore, the company had earlier announced that the nasal vaccine would price at Rs. 325 per shot for procurement by the government, and Rs. 800 per shot for private vaccination centres. The nasal vaccine can be taken after six months of the second dose.
Mango News Link
Telegram: https://t.me/mangonewsofficial
Google Play Store: https://bit.ly/2R4cbgN
Apple / iOS Store: https://apple.co/2xEYFJ
